GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CNBX Pharmaceuticals Inc (OTCPK:CNBX) » Definitions » EV-to-Revenue

CNBX Pharmaceuticals (CNBX Pharmaceuticals) EV-to-Revenue : 2.94 (As of May. 15, 2024)


View and export this data going back to 2007. Start your Free Trial

What is CNBX Pharmaceuticals EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, CNBX Pharmaceuticals's enterprise value is $1.59 Mil. CNBX Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Feb. 2024 was $0.54 Mil. Therefore, CNBX Pharmaceuticals's EV-to-Revenue for today is 2.94.

The historical rank and industry rank for CNBX Pharmaceuticals's EV-to-Revenue or its related term are showing as below:

CNBX' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.91   Med: 3243.73   Max: 30117.82
Current: 2.94

During the past 13 years, the highest EV-to-Revenue of CNBX Pharmaceuticals was 30117.82. The lowest was 2.91. And the median was 3243.73.

CNBX's EV-to-Revenue is ranked better than
73.7% of 1038 companies
in the Biotechnology industry
Industry Median: 7.97 vs CNBX: 2.94

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-15), CNBX Pharmaceuticals's stock price is $0.0107. CNBX Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Feb. 2024 was $0.04. Therefore, CNBX Pharmaceuticals's PS Ratio for today is 0.26.


CNBX Pharmaceuticals EV-to-Revenue Historical Data

The historical data trend for CNBX Pharmaceuticals's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CNBX Pharmaceuticals EV-to-Revenue Chart

CNBX Pharmaceuticals Annual Data
Trend Aug14 Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,155.54 3,574.64 - 197.27 3.89

CNBX Pharmaceuticals Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 56.88 4.77 3.89 3.15 3.02

Competitive Comparison of CNBX Pharmaceuticals's EV-to-Revenue

For the Biotechnology subindustry, CNBX Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CNBX Pharmaceuticals's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CNBX Pharmaceuticals's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where CNBX Pharmaceuticals's EV-to-Revenue falls into.



CNBX Pharmaceuticals EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

CNBX Pharmaceuticals's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=1.588/0.54
=2.94

CNBX Pharmaceuticals's current Enterprise Value is $1.59 Mil.
CNBX Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.54 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CNBX Pharmaceuticals  (OTCPK:CNBX) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

CNBX Pharmaceuticals's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.0107/0.041
=0.26

CNBX Pharmaceuticals's share price for today is $0.0107.
CNBX Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.04.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CNBX Pharmaceuticals EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of CNBX Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


CNBX Pharmaceuticals (CNBX Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
No. 3 Bethesda Metro Center, Suite 700, Bethesda, MD, USA, 20814
CNBX Pharmaceuticals Inc is a biotechnology company. It develops pharmaceuticals focusing on cancer research utilizing HTS technology and personalized bioinformatics tools. The company's main focus is the development of cannabinoid therapies and other technologies for the treatment of cancer, mainly cancers of the gastrointestinal tract, skin, breast, and prostate. The firm's main product is the RCC-33, an oral capsule for the treatment of colorectal cancer. The company tools include delivery systems, personalized medicine diagnostics, and therapies based on Cannabinoid compounds.
Executives
Cannabics Inc. 10 percent owner 108 WEST 13TH ST., WILMINGTON DE 19801
Thomas E Mills director, officer: President, CEO, CFO
North American Mining Corp 10 percent owner 6767 WEST TROPICANA AVENUE, SUITE 229, LAS VEGAS NV 89103
Lou Hilford director, officer: Vice-President, Secretary